Springer Frontiers in Ovarian Cancer Science (Comprehensive Gynecology and Obstetrics)

This volume presents the latest advances and the current status of our understanding regarding ovarian cancer, addressing both the basic and clinical aspects of the disease. In terms of basic medicine, the WHO Classification of Tumors of Female Reproductive Organs was revised in 2014, and that version addresses several new concepts and histopathological classifications not previously included. One of the most revolutionary breakthroughs concerns the genesis of epithelial ovarian tumors, shifting the focus from the ovarian surface epithelium to serous tubal intraepithelial carcinomas. Clinically, the mortality rate of epithelial ovarian cancer has gradually increased over the past few decades, making it essential to pursue multidisciplinary treatment and apply novel techniques such as neoadjuvant chemotherapy in daily clinical practice. The primary clinical task is the effective treatment of recurrent ovarian cancer with early palliative medicine. Fertility-sparing surgery may also be pursued depending on histologic subtypes, stage, extent of disease, and preexisting ovarian reserve with the concept of oncofertility. On the basis of the considerations described above, each expert author elucidates the science of ovarian cancer in detail, thus providing a collection that will benefit young medical oncologists and seasoned gynecologists and obstetricians alike. From the Back Cover This volume presents the latest advances and the current status of our understanding regarding ovarian cancer, addressing both the basic and clinical aspects of the disease. In terms of basic medicine, the WHO Classification of Tumors of Female Reproductive Organs was revised in 2014, and that version addresses several new concepts and histopathological classifications not previously included. One of the most revolutionary breakthroughs concerns the genesis of epithelial ovarian tumors, shifting the focus from the ovarian surface epithelium to serous tubal intraepithelial carcinomas. Clinically, the mortality rate of epithelial ovarian cancer has gradually increased over the past few decades, making it essential to pursue multidisciplinary treatment and apply novel techniques such as neoadjuvant chemotherapy in daily clinical practice. The primary clinical task is the effective treatment of recurrent ovarian cancer with early palliative medicine. Fertility-sparing surgery may also be pursued depending on histologic subtypes, stage, extent of disease, and preexisting ovarian reserve with the concept of oncofertility. On the basis of the considerations described above, each expert author elucidates the science of ovarian cancer in detail, thus providing a collection that will benefit young medical oncologists and seasoned gynecologists and obstetricians alike. About the Author Hidetaka Katabuchi, M.D., Ph.D. Professor and Chairman, Department of Obstetrics and Gynecology, Faculty of Life Sciences, Kumamoto University, Japan Gynecologic Oncology Committee Chairman, Japanese Society of Obstetrics and Gynecology Standing Director, Japan Society of Gynecological Oncology Executive Board Member, Japan Society of Clinical Oncology Dr. Katabuchi received his doctorates from the Kumamoto University Graduate School of Medicine. After completing his post-doctoral research at the Department of Pathology of the Johns Hopkins University, he became an associate professor at Kumamoto University in 2003 and was promoted to full professor in 2004. He is specialized in gynecologic pathology and is also a prominent oncologist, especially in the area of ovarian cancer. As a chairman of the Guidelines Committee in the Japanese Society of Gynecologic Oncology, he has engaged in the editing of guidelines for various gynecologic cancers from 2012 to 2016.